皮质类固醇注射用于缓解疼痛和运动范围在粘合性囊炎
Muhammad Mannan1, Syed Muneeb Ali Shah2,3, Zawar Ahmad4,2
1Orthopedic Surgery, University Hospitals Birmingham NHS Foundation Trust, Birmingham, GBR.
Cureus
|September 22, 2025
概括
关节内皮质类固醇注射适度治疗结的肩膀 (粘合性囊炎). 在12周后,超过一半的患者经历了疼痛缓解和肩膀运动范围的改善.
科学领域:
- 整形外科 整形外科 整形外科
- 疼痛管理 疼痛管理
- 肌肉骨系统疾病 肌肉骨系统疾病
背景情况:
- 粘着性囊炎,或冷的肩膀,导致慢性肩膀疼痛和硬.
- 对于冷肩部的最佳皮质类固醇注射策略仍在调查中.
- 有限的区域数据存在于结肩部的皮质类固醇注射疗效.
研究的目的:
- 为了评估粘合性囊炎的关节内皮质类固醇注射.
- 测量疼痛减轻和运动范围 (ROM) 的改善.
- 通过12周的特定疼痛和ROM改善值来定义疗效.
主要方法:
- 在148名粘着性囊炎患者的准实验性研究中.
- 在关节内注射Depo-Medrol和lignocaine通过后部方法.
- 12周的随访评估疼痛 (VAS) 和ROM,没有辅助治疗.
主要成果:
- 平均年龄为48.99岁,平均BMI为25.07公斤/米2.
- 基线VAS得分平均为6.12,症状持续时间为13.17周.
- 53.4%的患者在12周内获得了疗效 (确定的疼痛缓解和ROM改善).
结论:
- 关节内皮质类固醇注射对粘附性囊炎具有中度的有效性.
- 超过一半的患者获得了显著的疼痛缓解和功能改善.
- 皮质类固醇注射为冷肩部症状提供了可行的治疗选择.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
439
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
439
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
1.5K
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
1.5K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
493
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
493
Drug Delivery: Miscellaneous Routes
715
Drug delivery methods like oral inhalation, nasal sprays, transdermal patches, eye drops, intravitreal injection, and rectal administration provide localized effects with reduced toxicity.
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
715
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
499
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
499


